Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2013

View Archived Issues

XL-protein presents novel PASylated biopharmaceuticals

A potential new protein biomarker of erectile dysfunction

Promising in vitro results for a novel gene therapy for mitochondrial diseases

Novel models developed for skin diseases and SLE

Novel TRVP1 ligands disclosed by Grunenthal

Intervet International prepares new DGAT1 inhibitors

French group divulges new cystathione beta-synthase inhibitors

MedImmune presents novel antibodies targeting P. aeruginosa

Alios BioPharma begins phase I trial of first-in-class nucleoside analogue targeting RSV

Achillion Pharmaceuticals chooses novel HCV drug candidate for clinical development

Inostics receives CLIA certification for blood-based mutation testing

VBL Therapeutics presents phase I/II results for VB-111

IND-enabling study of stem cell candidate for Parkinson's disease commences

GC-1008 is well tolerated but shows no clinical benefit in patients with glioma

Grant supports Epitarget's work to develop nanoparticulate immune stimulator

Vanda Pharmaceuticals submits NDA for tasimelteon

Omeros' OMS-824 shows binding to PDE10 in PET scans

Cancer Research UK launches phase I trial of AZD-3965

E Keppra approved in Japan for pediatric epilepsy

Filgrastim biosimilars launched in Japan

European CHMP recommends approval of pomalidomide for rrMM

Novo Nordisk seeks E.U. approval of IDegLira for type 2 diabetes

Depomed to cease investment in Sefelsa following receipt of complete response letter from FDA

Otsuka files application in Japan for tolvaptan in autosomal dominant polycystic kidney disease

European CHMP recommends approval of Lojuxta

CMDh endorses EMA committee's recommendation on benefit/risk profile of Diane-35

CHMP recommends European approval of once-weekly somatropin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...